1. //
  2. Start
  3. //
  4. Publications
  5. Plasmid DNA vaccines against cancer.
  6. Output formats
  7. //

Plasmid DNA vaccines against cancer. Cytotoxic T-lymphocyte induction against tumor antigens

Research output: Journal contributions › Scientific review articles › Research

Standard

Plasmid DNA vaccines against cancer. Cytotoxic T-lymphocyte induction against tumor antigens. / Pavlenko, Maxim ; Leder, Christoph; Pisa, Pavel .
In: Expert Review of Vaccines, Vol. 4, No. 3, 01.06.2005, p. 315-327.

Research output: Journal contributions › Scientific review articles › Research

Harvard

Pavlenko, M, Leder, C & Pisa, P 2005, 'Plasmid DNA vaccines against cancer. Cytotoxic T-lymphocyte induction against tumor antigens', Expert Review of Vaccines, vol. 4, no. 3, pp. 315-327. https://doi.org/10.1586/14760584.4.3.315

APA

Pavlenko, M., Leder, C., & Pisa, P. (2005). Plasmid DNA vaccines against cancer. Cytotoxic T-lymphocyte induction against tumor antigens. Expert Review of Vaccines, 4(3), 315-327. https://doi.org/10.1586/14760584.4.3.315

Vancouver

Pavlenko M, Leder C, Pisa P. Plasmid DNA vaccines against cancer. Cytotoxic T-lymphocyte induction against tumor antigens. Expert Review of Vaccines. 2005 Jun 1;4(3):315-327. doi: 10.1586/14760584.4.3.315

Bibtex

@article{f42f29ba17c646ce8a7d941223a9eb2a,
title = "Plasmid DNA vaccines against cancer.: Cytotoxic T-lymphocyte induction against tumor antigens",
abstract = "In recent years, a number of tumor vaccination strategies have been developed. Most of these rely on the identification of tumor antigens that can be recognized by the immune system. DNA vaccination represents one such approach for the induction of both humoral and cellular immune responses against tumor antigens. Studies in animal models have demonstrated the feasibility of utilizing DNA vaccination to elicit protective antitumor immune responses. However, most tumor antigens expressed by cancer cells in humans are weakly immunogenic, and therefore require the development of strategies to potentiate DNA vaccine efficacy in the clinical setting. This review focuses on recent advances in understanding of the immunology of DNA vaccines, as well as strategies used to increase DNA vaccine potency with respect to cytotoxic T-lymphocyte activity.",
keywords = "Biology, Cancer, Clinical trial, Cytotoxic T-lymphocyte, DNA vaccine, Immunization, Tumor antigen",
author = "Maxim Pavlenko and Christoph Leder and Pavel Pisa",
note = "Funding Information: The authors thank A Miller for reviewing the manuscript. Supported in part by grants from the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, the EU 6-FP {\textquoteleft}ALLOSTEM{\textquoteright} (LSHB-CT-2004–502219) and US Department of Defense Prostate Cancer Research Program (PC030958).",
year = "2005",
month = jun,
day = "1",
doi = "10.1586/14760584.4.3.315",
language = "English",
volume = "4",
pages = "315--327",
journal = "Expert Review of Vaccines",
issn = "1744-8395",
publisher = "Expert Reviews",
number = "3",

}

RIS

TY - JOUR

T1 - Plasmid DNA vaccines against cancer.

T2 - Cytotoxic T-lymphocyte induction against tumor antigens

AU - Pavlenko, Maxim

AU - Leder, Christoph

AU - Pisa, Pavel

N1 - Funding Information: The authors thank A Miller for reviewing the manuscript. Supported in part by grants from the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, the EU 6-FP ‘ALLOSTEM’ (LSHB-CT-2004–502219) and US Department of Defense Prostate Cancer Research Program (PC030958).

PY - 2005/6/1

Y1 - 2005/6/1

N2 - In recent years, a number of tumor vaccination strategies have been developed. Most of these rely on the identification of tumor antigens that can be recognized by the immune system. DNA vaccination represents one such approach for the induction of both humoral and cellular immune responses against tumor antigens. Studies in animal models have demonstrated the feasibility of utilizing DNA vaccination to elicit protective antitumor immune responses. However, most tumor antigens expressed by cancer cells in humans are weakly immunogenic, and therefore require the development of strategies to potentiate DNA vaccine efficacy in the clinical setting. This review focuses on recent advances in understanding of the immunology of DNA vaccines, as well as strategies used to increase DNA vaccine potency with respect to cytotoxic T-lymphocyte activity.

AB - In recent years, a number of tumor vaccination strategies have been developed. Most of these rely on the identification of tumor antigens that can be recognized by the immune system. DNA vaccination represents one such approach for the induction of both humoral and cellular immune responses against tumor antigens. Studies in animal models have demonstrated the feasibility of utilizing DNA vaccination to elicit protective antitumor immune responses. However, most tumor antigens expressed by cancer cells in humans are weakly immunogenic, and therefore require the development of strategies to potentiate DNA vaccine efficacy in the clinical setting. This review focuses on recent advances in understanding of the immunology of DNA vaccines, as well as strategies used to increase DNA vaccine potency with respect to cytotoxic T-lymphocyte activity.

KW - Biology

KW - Cancer

KW - Clinical trial

KW - Cytotoxic T-lymphocyte

KW - DNA vaccine

KW - Immunization

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=22144482377&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/bdf61cf5-c530-3d6f-875f-2f4f734f71bb/

U2 - 10.1586/14760584.4.3.315

DO - 10.1586/14760584.4.3.315

M3 - Scientific review articles

C2 - 16026247

VL - 4

SP - 315

EP - 327

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1744-8395

IS - 3

ER -

DOI